{"protocolSection":{"identificationModule":{"nctId":"NCT00696709","orgStudyIdInfo":{"id":"V212-004"},"secondaryIdInfos":[{"id":"V212-004","type":"OTHER","domain":"Merck"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)","officialTitle":"A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2019-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-12-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2009-11-16","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11-16","type":"ACTUAL"},"studyFirstSubmitDate":"2008-06-11","studyFirstSubmitQcDate":"2008-06-12","studyFirstPostDateStruct":{"date":"2008-06-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-10-18","resultsFirstSubmitQcDate":"2019-10-18","resultsFirstPostDateStruct":{"date":"2019-11-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-10-18","lastUpdatePostDateStruct":{"date":"2019-11-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic when administered to healthy individuals, as measured by VZV-specific antibody responses by glycoprotein enzyme-linked immunosorbent assay (gpELISA). The primary hypothesis was that gamma-irradiated VZV vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) would elicit an acceptable VZV-specific immune response. The secondary hypothesis for Part 1 of the study was that heat-treated VZV vaccine would elicit an acceptable VZV-specific immune response."},"conditionsModule":{"conditions":["Herpes Zoster"],"keywords":["Herpes Zoster (Shingles)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":290,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","type":"EXPERIMENTAL","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered \\~30 days apart.","interventionNames":["Biological: Comparator: V212"]},{"label":"Part 1: Gamma- Irradiated VZV Vaccine A","type":"EXPERIMENTAL","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart.","interventionNames":["Biological: Comparator: V212"]},{"label":"Part 1: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart.","interventionNames":["Biological: Comparator: Placebo"]},{"label":"Part 2: Gamma- Irradiated VZV Vaccine B","type":"EXPERIMENTAL","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart.","interventionNames":["Biological: Comparator: V212"]},{"label":"Part 2: Gamma- Irradiated VZV Vaccine C","type":"EXPERIMENTAL","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart.","interventionNames":["Biological: Comparator: V212"]}],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: V212","description":"0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart","armGroupLabels":["Part 1: Gamma- Irradiated VZV Vaccine A","Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","Part 2: Gamma- Irradiated VZV Vaccine B","Part 2: Gamma- Irradiated VZV Vaccine C"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","description":"Placebo; 4-dose regimen administered \\~30 days apart.","armGroupLabels":["Part 1: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1: Geometric Mean Fold Rise of the Varicella-Zoster Virus (VZV)-Specific Immune Responses Measured by Glycoprotein Enzyme-Linked Immunosorbent Assay in Gamma-Irradiated VZV Vaccine A Recipients","description":"Serum samples were tested for antibody response using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) in gamma-irradiated VZV vaccine A recipients. The geometric mean fold rise (GMFR) is the response at approximately 28 days postdose 4 / response predose on Day 1. This outcome measure applied only to participants who received VZV vaccine A; heat-treated VZV vaccine and placebo participants were not assessed for this outcome.","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)"},{"measure":"Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine B Recipients","description":"Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine B recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)"},{"measure":"Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine C Recipients","description":"Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine C recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)"},{"measure":"Percentage of Participants With a Serious Adverse Event","description":"A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, or is a congenital anomaly or birth defect. The percentage of participants with one or more SAEs was assessed.","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)"},{"measure":"Percentage of Participants With an Injection-Site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs included redness, swelling, and pain/tenderness/soreness. The percentage of participants with one or more VRC prompted injection-site AE was assessed with incidence \\> 0% in one or more vaccination groups.","timeFrame":"Up to Day 5 post any vaccination (Up to ~5 days)"},{"measure":"Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and herpes zoster (HZ)-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed with incidence \\> 0% in one or more vaccination groups.","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)"},{"measure":"Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card","description":"Elevated temperature is defined as ≥100.5 °F (≥38.1 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)"},{"measure":"Percentage of Participants Who Discontinued the Study Drug Due to an Adverse Event","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who discontinued the study drug due to one or more AEs was assessed.","timeFrame":"Up to Dose 4 (Up to ~90 days)"}],"secondaryOutcomes":[{"measure":"Part 1: Geometric Mean Fold Rise of the Heat-Treated VZV-Specific Immune Responses Measured by gpELISA","description":"Serum samples were tested for antibody response using gpELISA in heat-treated VZV vaccine recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be 50 to 59 years of age\n* No fever on vaccination days\n* Must have had chickenpox or lived in an area where the chickenpox virus is prevalent for 30 or more years\n* Females of child-bearing potential must use acceptable forms of birth control\n\nExclusion Criteria:\n\n* Prior history of shingles\n* Prior receipt of any chickenpox or shingles vaccine\n* Pregnant or breastfeeding\n* Received or expect to receive a live virus vaccine (such as measles, mumps, rubella) from 4 weeks before the first visit through the last visit\n* Received or expect to receive an inactivated vaccine (such as tetanus or pneumonia) from 7 days before the first visit through the last visit\n* Received immunoglobulin or blood products\n* Receiving treatment that may weaken the immune system\n* Have an immune system disorder","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"59 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"In Part 1, all participants received heat-treated varicella zoster virus (VZV) vaccine, gamma-irradiated VZV vaccine A or placebo administered as a 4-dose regimen approximately every 30 days. In Part 2, all participants received either gamma-irradiated VZV vaccine B or C administered as a 4-dose regimen approximately every 30 days.","recruitmentDetails":"The study was performed in 2 parts - Part 1 and Part 2, with a total of 160 participants.","groups":[{"id":"FG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"FG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"FG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"FG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"FG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"64"},{"groupId":"FG004","numSubjects":"65"}]},{"type":"Vaccination 1 (Day 1)","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"64"},{"groupId":"FG004","numSubjects":"65"}]},{"type":"Vaccination 2 (~Day 30)","achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"61"},{"groupId":"FG004","numSubjects":"64"}]},{"type":"Vaccination 3 (~Day 60)","achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"59"},{"groupId":"FG004","numSubjects":"63"}]},{"type":"Vaccination 4 (~Day 90)","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"59"},{"groupId":"FG004","numSubjects":"63"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"59"},{"groupId":"FG004","numSubjects":"62"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"BG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"BG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"BG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"BG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"64"},{"groupId":"BG004","value":"65"},{"groupId":"BG005","value":"290"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.0","spread":"2.6"},{"groupId":"BG001","value":"54.0","spread":"2.5"},{"groupId":"BG002","value":"54.0","spread":"2.9"},{"groupId":"BG003","value":"53.9","spread":"3.0"},{"groupId":"BG004","value":"54.6","spread":"3.1"},{"groupId":"BG005","value":"54.1","spread":"2.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"42"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"193"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"97"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Geometric Mean Fold Rise of the Varicella-Zoster Virus (VZV)-Specific Immune Responses Measured by Glycoprotein Enzyme-Linked Immunosorbent Assay in Gamma-Irradiated VZV Vaccine A Recipients","description":"Serum samples were tested for antibody response using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) in gamma-irradiated VZV vaccine A recipients. The geometric mean fold rise (GMFR) is the response at approximately 28 days postdose 4 / response predose on Day 1. This outcome measure applied only to participants who received VZV vaccine A; heat-treated VZV vaccine and placebo participants were not assessed for this outcome.","populationDescription":"The analysis population included all gamma-irradiated VZV vaccine A participants who received all 4 vaccinations with no protocol deviations; heat-treated VZV vaccine, vaccine B, vaccine C and placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)","groups":[{"id":"OG000","title":"Part 1: Gamma- Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","lowerLimit":"1.82","upperLimit":"2.61"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0.","statisticalMethod":"Longitudinal regression (LR)","statisticalComment":"Calculated based on LR model (adjusting for pre-vaccination immunogenicity level and incomplete data) with visit as covariate."}]},{"type":"PRIMARY","title":"Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine B Recipients","description":"Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine B recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","populationDescription":"The analysis population included all gamma-irradiated VZV vaccine B participants who received all 4 vaccinations with no protocol deviations; heat-treated VZV vaccine, vaccine A, vaccine C and placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)","groups":[{"id":"OG000","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","lowerLimit":"1.57","upperLimit":"2.29"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0.","statisticalMethod":"Longitudinal regression (LR)","statisticalComment":"Calculated based on LR model (adjusting for pre-vaccination immunogenicity level and incomplete data) with visit as covariate."}]},{"type":"PRIMARY","title":"Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine C Recipients","description":"Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine C recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","populationDescription":"The analysis population included all gamma-irradiated VZV vaccine C participants who received all 4 vaccinations and had no protocol deviations; heat-treated VZV vaccine, vaccine A, vaccine B and placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)","groups":[{"id":"OG000","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","lowerLimit":"1.35","upperLimit":"1.84"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0.","statisticalMethod":"Longitudinal regression (LR)","statisticalComment":"Calculated based on LR model (adjusting for pre-vaccination immunogenicity level and incomplete data) with visit as covariate."}]},{"type":"SECONDARY","title":"Part 1: Geometric Mean Fold Rise of the Heat-Treated VZV-Specific Immune Responses Measured by gpELISA","description":"Serum samples were tested for antibody response using gpELISA in heat-treated VZV vaccine recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.","populationDescription":"The analysis population included all heat-treated VZV vaccine participants who received all 4 vaccinations and had no protocol deviations; vaccine A, vaccine B, vaccine C and placebo participants were not assessed for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline and ~28 days Postdose 4 (~Day 118)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","lowerLimit":"1.78","upperLimit":"2.48"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","nonInferiorityComment":"The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \\>1.0.","pValue":"<0.0001","statisticalMethod":"Longitudinal data analysis (LDA)","statisticalComment":"LDA with log-transformed VZV responses at each visit as response variables and visit as covariate."}]},{"type":"PRIMARY","title":"Percentage of Participants With a Serious Adverse Event","description":"A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, or is a congenital anomaly or birth defect. The percentage of participants with one or more SAEs was assessed.","populationDescription":"The analysis population included all participants who received at least one dose of vaccine and who had any safety follow-up based on the actual vaccination received. Participants were excluded if they received an incorrect vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"OG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"OG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"1.6"},{"groupId":"OG004","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.8","ciUpperLimit":"5.7","estimateComment":"Miettinen \\& Nurminen"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.2","ciUpperLimit":"8.8","estimateComment":"Miettinen \\& Nurminen"}]},{"type":"PRIMARY","title":"Percentage of Participants With an Injection-Site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs included redness, swelling, and pain/tenderness/soreness. The percentage of participants with one or more VRC prompted injection-site AE was assessed with incidence \\> 0% in one or more vaccination groups.","populationDescription":"The analysis population included all participants who received at least one dose of vaccine and who had any safety follow-up based on the actual vaccination received. Participants were excluded if they received an incorrect vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to Day 5 post any vaccination (Up to ~5 days)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"OG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"OG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8"},{"groupId":"OG001","value":"62.3"},{"groupId":"OG002","value":"21.9"},{"groupId":"OG003","value":"63.5"},{"groupId":"OG004","value":"50.8"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentage","paramValue":"35.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"15.2","ciUpperLimit":"52.6"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentage","paramValue":"40.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"19.6","ciUpperLimit":"57.0"}]},{"type":"PRIMARY","title":"Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and herpes zoster (HZ)-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed with incidence \\> 0% in one or more vaccination groups.","populationDescription":"The analysis population included all participants who received at least one dose of vaccine and who had any safety follow-up based on the actual vaccination received. Participants were excluded if they received an incorrect vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"OG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"OG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3"},{"groupId":"OG001","value":"54.1"},{"groupId":"OG002","value":"50.0"},{"groupId":"OG003","value":"52.4"},{"groupId":"OG004","value":"41.5"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"-4.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25.3","ciUpperLimit":"16.1","estimateComment":"Miettinen \\& Nurminen"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"4.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.9","ciUpperLimit":"24.9","estimateComment":"Miettinen \\& Nurminen"}]},{"type":"PRIMARY","title":"Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card","description":"Elevated temperature is defined as ≥100.5 °F (≥38.1 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.","populationDescription":"The analysis population included all participants who received at least one dose of vaccine and who had any safety follow-up based on the actual vaccination received. Participants were excluded if they received an incorrect vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to ~28 days Postdose 4 (Up to ~118 days)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"OG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"OG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"3.2"},{"groupId":"OG004","value":"1.5"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"0.480","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentage","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.3","ciUpperLimit":"8.4"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"0.469","statisticalMethod":"Miettinen & Nurminen","paramType":"Difference in Percentage","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.2","ciUpperLimit":"8.8"}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued the Study Drug Due to an Adverse Event","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who discontinued the study drug due to one or more AEs was assessed.","populationDescription":"The analysis population included all participants who received at least one dose of vaccine and who had any safety follow-up based on the actual vaccination received. Participants were excluded if they received an incorrect vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to Dose 4 (Up to ~90 days)","groups":[{"id":"OG000","title":"Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated VZV vaccine A; 4-dose regimen administered \\~30 days apart."},{"id":"OG001","title":"Part 1: Gamma-Irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \\~30 days apart"},{"id":"OG002","title":"Part 1: Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart."},{"id":"OG003","title":"Part 2: Gamma-Irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \\~30 days apart."},{"id":"OG004","title":"Part 2: Gamma-Irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \\~30 days apart."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"1.6"},{"groupId":"OG004","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.8","ciUpperLimit":"5.7","estimateComment":"Miettinen \\& Nurminen"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.8","ciUpperLimit":"6.0","estimateComment":"Miettinen \\& Nurminen"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to ~28 days Postdose 4 (up to ~118 days)","description":"All participants who received at least one dose of vaccine and who had any safety follow-up were included in the safety evaluation, based on the actual vaccination received. Participants were excluded from the safety analysis population if they received an incorrect vaccination.","eventGroups":[{"id":"EG000","title":"Part 1 Heat-treated VZV Vaccine","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart.","deathsNumAffected":0,"deathsNumAtRisk":64,"seriousNumAffected":0,"seriousNumAtRisk":64,"otherNumAffected":47,"otherNumAtRisk":64},{"id":"EG001","title":"Gamma-irradiated VZV Vaccine A","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart.","deathsNumAffected":0,"deathsNumAtRisk":61,"seriousNumAffected":1,"seriousNumAtRisk":61,"otherNumAffected":48,"otherNumAtRisk":61},{"id":"EG002","title":"Placebo","description":"Participants received a 4-dose placebo regimen administered \\~30 days apart.","deathsNumAffected":0,"deathsNumAtRisk":32,"seriousNumAffected":0,"seriousNumAtRisk":32,"otherNumAffected":20,"otherNumAtRisk":32},{"id":"EG003","title":"Part 2 Gamma-irradiated VZV Vaccine B","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart.","deathsNumAffected":0,"deathsNumAtRisk":63,"seriousNumAffected":1,"seriousNumAtRisk":63,"otherNumAffected":47,"otherNumAtRisk":63},{"id":"EG004","title":"Gamma-irradiated VZV Vaccine C","description":"Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \\~30 days apart.","deathsNumAffected":0,"deathsNumAtRisk":65,"seriousNumAffected":0,"seriousNumAtRisk":65,"otherNumAffected":43,"otherNumAtRisk":65}],"seriousEvents":[{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Breast cancer stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]}],"otherEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Eye allergy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Scleral disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":29,"numAtRisk":64},{"groupId":"EG001","numEvents":73,"numAffected":31,"numAtRisk":61},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG003","numEvents":69,"numAffected":28,"numAtRisk":63},{"groupId":"EG004","numEvents":73,"numAffected":27,"numAtRisk":65}]},{"term":"Injection site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":32,"numAtRisk":64},{"groupId":"EG001","numEvents":79,"numAffected":36,"numAtRisk":61},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":32},{"groupId":"EG003","numEvents":86,"numAffected":40,"numAtRisk":63},{"groupId":"EG004","numEvents":73,"numAffected":32,"numAtRisk":65}]},{"term":"Injection site papule","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":11,"numAffected":7,"numAtRisk":63},{"groupId":"EG004","numEvents":8,"numAffected":5,"numAtRisk":65}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":29,"numAtRisk":64},{"groupId":"EG001","numEvents":42,"numAffected":20,"numAtRisk":61},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG003","numEvents":53,"numAffected":24,"numAtRisk":63},{"groupId":"EG004","numEvents":60,"numAffected":24,"numAtRisk":65}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Vessel puncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Allergy to arthropod bite","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Bed bug infestation","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Clostridial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Conjunctivitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Kidney infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":61},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":5,"numAffected":2,"numAtRisk":65}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Epicondylitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Joint sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Stress fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Synovial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Nodule on extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":65}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":61},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG003","numEvents":19,"numAffected":9,"numAtRisk":63},{"groupId":"EG004","numEvents":19,"numAffected":8,"numAtRisk":65}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":65}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Generalised anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Allergic sinusitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":1,"numAtRisk":65}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Nasal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":5,"numAffected":3,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Paranasal sinus hypersecretion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":7,"numAffected":1,"numAtRisk":65}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Upper respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dermatitis atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Heat rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":65}]},{"term":"Rash generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Rash vesicular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":61},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Rosacea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Skin burning sensation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Skin swelling","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":63},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":65}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D006562","term":"Herpes Zoster"}],"ancestors":[{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}